Invea Therapeutics

Inflammatory disease biotech Invea Therapeutics refiles for a $35 million IPO     Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, filed on Monday with the SEC to raise up to $35 million in an initial... Read more